As shown in Figure S1, in the entire GSE10846 series patients, we found that DLBCL patients with high risk scores tended to express high levels of risky genes (IL6 and IL1A) in their tumors, whereas patients with low risk scores tended to express high levels of protective genes (CSF3). This evidence concerns the gene IL6 and diffuse large B-cell lymphoma.